Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

151.35 -2.92 (-1.89%)
Streaming Delayed Price Updated: 12:13 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
From Biogen Inc.
Via GlobeNewswire
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above... 
Via StockStory
Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations
Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was... 
Via StockStory
Topics Artificial Intelligence
Earnings Scheduled For October 30, 2025
 
Via Benzinga
Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal
Via Stocktwits
Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide
Biogen stock fell early Thursday after the biotech company cut its 2025 profit outlook due to an expected tax charge. 
Via Investor's Business Daily
Examining the Future: Biogen's Earnings Outlook
 
Via Benzinga
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases. 
Via Benzinga
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
From Biogen Inc.
Via GlobeNewswire
3 Profitable Stocks We Steer Clear Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
From Biogen Inc.
Via GlobeNewswire
ARPA-H Taps Former DARPA Innovator to Ignite High-Risk, High-Reward Health Tech Revolution
In a move poised to reshape the landscape of biomedical innovation, the United States government officially appointed Dr. Renee Wegrzyn, a distinguished former official from the Defense Advanced... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
Via The Motley Fool
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 26.6% to $146 per share while the index has gained 26.5%. 
Via StockStory
Topics Government Stocks World Trade
1 Healthcare Stock to Research Further and 2 We Find Risky
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
From Biogen Inc.
Via GlobeNewswire
Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)
Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
7 Analysts Have This To Say About Biogen
 
Via Benzinga
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
1 Value Stock with Promising Prospects and 2 We Avoid
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Which S&P500 stocks are moving on Monday?
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Nasdaq 100 Top 25,000 As AMD Spikes, Gold Eyes $4,000: What's Moving Markets Monday?
Tech and AI-related stocks continued to propel Wall Street to new record highs Monday, with Advanced Micro Devices Inc. (NASDAQ:AMD) surging nearly 30% after unveiling a landmark investment in OpenAI. 
Via Benzinga
Monday's session: top gainers and losers in the S&P500 index
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Breakthrough in Alzheimer’s Diagnostics: University of Liverpool Unveils Low-Cost, Handheld AI Blood Test
In a monumental stride towards democratizing global healthcare, researchers at the University of Liverpool have announced the development of a pioneering low-cost, handheld, AI-powered blood test... 
Via TokenRing AI
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.